| name | es-gh-treatment-timing |
| description | This skill determines the appropriate timing for initiating growth hormone (GH) therapy in childhood cancer survivors, recommending to wait until 1 year disease‑free after completion of malignant disease treatment to minimize risks. Triggers include clinician questions such as “When can I start GH therapy after cancer treatment completion?” or “How long should I wait to initiate growth hormone post‑remission?” |
Time GH initiation post‑malignant disease
STEP 1 — Gather Information
Record the date of malignant disease therapy completion, verify current disease‑free status (no evidence of disease on imaging/labs), and confirm GH deficiency status via provocative testing or IGF‑1 if appropriate; if any data are missing, obtain oncology follow‑up results before proceeding.
STEP 2 — Rule In / Rule Out
Is the patient disease‑free for at least 12 months?
- Yes → Rule in for GH initiation consideration.
- No → Rule out immediate GH initiation; recommend continued oncology surveillance and reassess disease‑free interval.
STEP 3 — Classify or Stratify
Among patients disease‑free ≥12 months, classify by GH deficiency status:
- GH deficient (positive provocative test) → Proceed to decide GH therapy.
- Not GH deficient → Advise against GH therapy for short stature and monitor growth.
STEP 4 — Decide
For GH‑deficient patients with disease‑free ≥12 months, decide to initiate GH therapy using standard pediatric weight‑based regimens; for non‑GH‑deficient patients, decide to withhold GH and continue routine growth monitoring.
Clinical Guardrails / Mimics / Pitfalls
Do not start GH therapy while active malignancy or within 12 months of therapy completion; avoid GH in patients receiving tyrosine kinase inhibitors; do not rely solely on IGF‑1 levels to diagnose GH deficiency; counsel against GH use in spinal radiation‑associated disproportionate growth without discussing risks of worsening scoliosis or slipped capital femoral epiphysis.
Concrete Clinical Example
A 12‑year‑old medulloblastoma survivor completed craniospinal irradiation 14 months ago, remains disease‑free, and has a low IGF‑1 with a failed insulin tolerance test confirming GH deficiency; GH therapy is initiated after confirming the disease‑free interval exceeds 12 months.
Source: Hypothalamic Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline, Sklar et al., 2018, DOI:10.1210/jc.2018-01175
TODO: consider adding scripts/calc.py for the es-gh-treatment-timing calculator
